跳至主要内容
临床试验/NCT02941211
NCT02941211已完成不适用

Effectiveness and Safety Evaluation of Aqueduct -100 Device

Aqueduct Medical Ltd2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2015年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
50
试验地点
2
主要终点
Percentage of patients with dilation of cervix to the diameter needed to perform the intrauterine procedure using Aqueduct-100 device.

研究概览

简要总结

Evaluation of efficacy and safety of using Aqueduct -100 - Cervical Dilator Device

详细描述

There are predominantly two major dilatation techniques that are employed in dilating the cervix. The first technique uses expansible dry solid material, such as laminaria (seaweed) is inserted into the cervix in its dried stiff form. In the cervix it comes into contact with body fluids that cause the laminaria to swell and enlarge the cervical cavity. The second more widespread procedure, involves the use of series of solid, rod like instruments of graduated diameter used in serial fashion by the physician (Hegar dilators). The physician first inserts a rod like dilator and replaces it with the dilator of next higher diameter. This procedure continues until adequate dilatation occurs.

The Problem is that each of the above-mentioned methods has its shortcomings: the use of the laminaria method (rarely done) requires preliminary patient visit, for insertion of the laminaria rod and is extremely slow and typically involves often as much as 10-12 hours for a significant amount of dilatation to occur.

The use of rod-like instruments (Hegar) requires general or regional anesthesia, when local anesthetics are used, the patient nevertheless frequently experiences a great amount of discomfort from the procedure. The mechanical dilatation of the cervix demands a large amount of longitudinal force that may damage or even puncture the cervix and the uterus.

Aqueduct 100 is a catheter for use in dilating various body cavities and especially the human cervix. The device will enable continuous, fast and safe dilatation of the cervix to a pre-determined diameter as a pre-procedure to intrauterine surgeries.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Subjects, females, 18 years of age or older.
  • Subjects undergoing any process that requires dilation (intrauterine procedures)
  • Subjects willing to sign informed consent form.

排除标准

  • Subjects younger than 18 years of age
  • Subject with sex transmitted diseases, or with infectious diseases (HIV, HCV).
  • Subjects unwilling to sign the informed consent form.

结局指标

主要结局

Percentage of patients with dilation of cervix to the diameter needed to perform the intrauterine procedure using Aqueduct-100 device.

时间窗: Through study completion, approximately 6 months

The primary outcome of this study is to determine the efficacy of the Aqueduct-100 device to dilate the uterine cervices to the desired diameter.

次要结局

  • Occurrence of Adverse Events(Through study completion, approximately 6 months)

研究者

发起方
Aqueduct Medical Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验